Gonzalez-Mujica, Freddy; Pradere, José D.; Gonzalez, Julio C.
Renal Glycosuria Induced by Acute Thioacetamide Administration to Rats
Universidad Central de Venezuela
Maracay, Venezuela

Available in: http://www.redalyc.org/articulo.oa?id=373139069005
**RENAL GLYCOSURIA INDUCED BY ACUTE THIOACETAMIDE ADMINISTRATION TO RATS**

**Glucosuria Renal Producida por la Administración Aguda de Tioacetamida en Ratas**

Freddy Gonzalez-Mujica*, José D. Pradere** and Julio C. Gonzalez***


Correo-E: gonzalef@cantv.net

**RESUMEN**

La administración de tioacetamida (TAA) en ratas (75 mg/kg de peso vía subcutánea) produjo un incremento estadísticamente significativo de la eliminación urinaria de glucosa, Na⁺ y fosfato. Adicionalmente, ocurrió una disminución de la presión arterial y de la velocidad de filtración glomerular, sin cambios en la excreción urinaria de K⁺, H⁺, aminoácidos ni en la glucemia. Se observó una disminución del 60% y 75% del Tₘₐₓ y Tₘᵢₙ para la glucosa, respectivamente. La TAA alteró la captación de [¹⁴C]-glucosa por vesículas de membrana de borde apical renal (BBMV), disminuyendo en un 16% el pico de captación a los 30 s, en un 63% la Vₘₐₓ y en aproximadamente un 82% el Kₘ. También disminuyó en un 52% el Kᵩ y cerca de un 59% el número de sitios de unión para [³H]-floricina en BBMV. Estos resultados sugieren fuertemente que la droga reduce la cantidad del co-transportador Na⁺/glucosa (SGLT₁) presente en la membrana apical del túbulo contorneado proximal. La disminución de la temperatura de transición de la maltasa y de la fosfatasa alcalina de las BBMV así como el incremento de la cantidad de ácidos grasos insaturados presentes en los fosfolípidos de las BBMV sugieren un incremento.

**ABSTRACT**

Thioacetamide (TAA) administration to rats (75 mg/kg body weight by subcutaneous injection) produced a statistically significant increase in the urinary excretion of glucose, Na⁺ and phosphate. In addition, there was a decrease in the arterial pressure and in the glomerular filtration rate, without changes in the urinary excretion of K⁺, H⁺, amino acids or in the glycaemia. Decreases of 60% and 75% were observed in the T_max and T_min for glucose, respectively. TAA intoxication reduced in 16% the overshoot, by almost 63% the V_max and by nearly 82% the K_m of the brush border membrane vesicles (BBMV) [¹⁴C]-glucose uptake. It also decreased about 52% the K_d and by almost 59% the number of binding sites of BBMV [³H]-phlorizin. These results strongly suggest that TAA reduces the amount of Na⁺/glucose co-transporter (SGLT₁) present in the apical membrane of the proximal renal tubule. An increase in the BBMV fluidity is suggested by the decrease in the BBMV maltase and alkaline phosphatase transition temperature and by the increase in the unsaturated fatty acids content of BBMV phospholipids. These results may explain the increase in SGLT₁ affinity for glucose evidenced by the decrease in the K_m.
Renal glycosuria by thioacetamide / Gonzalez-Mujica et al.

en la fluidez de dichas membranas. Estos resultados pudieran explicar el incremento en la afinidad del SGLT1 por la glucosa producida por la TAA.

(Palabras clave: Rata, tioacetamida, carcinógeno, glucosuria, SGLT1)

(Key words: Rat, thioacetamide, carcinogens, glycosuria, SGLT1)

INTRODUCTION

Thioacetamide (TAA) was originally used as a fungicide (Vadi and Neal, 1981). Thioacetamide is a weak carcinogen that mainly affects liver and kidney (Kleinfeld, 1957; Bruck et al., 2007; Hasegawa et al., 2007; Rekha et al., 2008) and causing the latter histological alterations in the proximal renal tubule (Baker and Smuckler, 1974), an increase in the size of the cortical kidney nuclei and nucleoli and a decrease in the glucose-6-phosphatase activity of the nuclear envelope (Inciarte and González-Mujica, 1988). At present, it is not clear if TAA has a general effect on macromolecules synthesis and/or degradation; however it has been shown that its administration reduces the expression of liver cytochrome P450 (Sathyabama and Padmanaban, 1984) and decreases the amount of liver nuclear envelope glucose-6-phosphatase (González-Mujica et al., 1993).

Lundsgaard (1933) postulated the phosphorylation/dephosphorylation theory to explain the glucose changes during its intestinal absorption; this theory claims the participation of both the hexokinase and glucose-6-phosphatase enzymes. However, the phlorizine dose required to inhibit the glucose phosphorylation/dephosphorylation is large in comparison to the amount needed to produce glycosuria (Taggart, 1958); furthermore the lack of glycosuria in patients with Von Gierke disease (Cori, 1954) permits to rule out the phosphorylation/dephosphorylation theory. However, recently it has been proved that in animals that do not express the glucose transporter 2 (GLUTS 2), glucose undergoes phosphorylation/dephosphorylation during its intestinal absorption (Stümpel et al., 2001). It is interesting to point out that the intestinal absorption and kidney reabsorption of glucose occur by a similar if not identical mechanism.

In view of the above results and of our findings, in preliminary experiments in which TAA treatment produced glycosuria in rats, we studied the effects of TAA on some kidney functions and on the Na+/glucose co-transporter (SGLT1) of the proximal renal tubule by measuring the BBMV D-[14C]-glucose uptake and the BBMV [3H]-phlorizin binding in order to estimate the amount of SGLT1 in the proximal tubule brush border membrane, also some lipid characteristics and, the fluidity of the BBMV were studied.

MATERIALS AND METHODS

Animals and treatments

Male Sprague-Dawley rats weighing 200-250 g and located at the Instituto de Medicina Experimental, Facultad de Medicina, Universidad Central de Venezuela, were used. The experimental group received a dose of TAA of 75 mg/kg of body weight; (Koch Ligh Lab, England) dissolved in 0.9% NaCl, at a concentration of 10 mg/mL, by subcutaneous injection during 3 consecutive days. The control group received an equivalent volume of a 0.9% NaCl solution. The rats were used 24 h after the last TAA dose was given. Two to four rats were kept in metallic cages with free access to food and water. The number of animals per experiment varied.

Kidney function

Rats were anesthetized by intraperitoneal injection of pentobarbital (60 mg/kg of body weight). Catheters were placed in the jugular vein, the carotid artery and the urinary bladder, respectively. Glomerular filtration rate was measured using inulin clearance. Animals were injected continuously by the vein with 28 µL/min. of 5% inulin in 0.9% NaCl. Forty minutes after the surgery was finished, samples
of blood (250 μL) and urine (all the volume present at that time) were collected every 20 minutes, up to a total of 5 samples. Inulin in blood and urine samples, was estimated as described by Heyrovsky, (1956).

To measure the tubular glucose reabsorption, rats were injected continuously through the vein with 28 μL/min. of increasing concentrations of glucose (5-30%). Blood and urine samples were collected as before. In blood and urine samples, glucose concentration was estimated by the glucose oxidase method (Lott and Turner, 1975). A glucose titration curve was constructed, following Robson et al. (1968).

Urinary elimination of several ions and compounds was carried out as follows: Na⁺ and K⁺ by flame spectrophotometer; phosphate (Fiske and Subbarow, 1925), H⁺ potenciometrically, and amino acids by colorimetric technique (Henry, 1969).

Also, the blood pressure was measured by placing a catheter in the carotid artery connected to a pressure transducer attached to a polygraph (Grass, model 7-B).

D-[U-14C]-glucose uptake by brush border membrane vesicles (BBMV) from proximal renal tubule

The BBMV were purified following Malathi et al. (1979). The relative purity of the fraction was estimated by electron microscopy (TEM Hitachi 500) and by measuring the activity of the following enzymes: succinate-cytochrome C reductase, NADH-cytochrome C reductase and β-glucuronidase for mitochondria, microsomes and lysosomes, respectively (Bergmeyer, 1963); Na⁺-K⁺-ATPase for basolateral membrane (Cohen et al., 1986), maltase (De Sa Moita et al., 1989) and alkaline phosphatase (Andersch and Szczypinski, 1947) as BBMV markers.

The maltase and alkaline phosphatase enzymes were also determined, using control and TAA treated BBMV at different temperatures (from 0 to 40 ºC) in order to draw an Arrhenius plot and calculate the activation energy (AE) and the transition temperature. Proteins were measured by Lowry et al. (1951).

The D-[U-14C]-glucose (2.5 mCi/mM Commissariat a L'energie atomique, France) uptake by BBMV obtained from control and TAA-treated rats was carried out as described by Malathi et al. (1979). The radioactivity was measured using a liquid scintillation counter (LKB Rackbeta) with 75% efficiency.

BBMV density

BBMV were placed on the top of a linear sucrose gradient (density 1.10-1.30 g/cm3) in 10 mM Tris-HCl pH: 7.4 and centrifuged at 50000 g for 16h at 4°C. For each gradient fraction, the 280 nm absorption and the refraction index were recorded.

Lipid extraction and separation

BBMV total lipids were extracted following Folch's method (Folch et al., 1975), the phospholipids were separated by silica G thin layer chromatography using petroleum ether: diethyl ether: acetic acid in a proportion of 90:10:1. The phospholipids phosphorus was estimated (Chen et al., 1956) after hydrolysis with concentrated perchloric acid at 180°C for 2 h. The methyl esters of fatty acid phospholipids were obtained (Kates, 1964). The fatty acid methyl esters were separated using a Hewlett Packard 4880 gas-liquid chromatographer with a glass column (0.4 x 184 cm) with diethylglycol adipate as stationary phase and nitrogen as mobile phase at a rate flow of 30 mL/min and a temperature of 200 ºC.

[3H]-phlorizin binding to BBMV from the proximal renal tubule

The [3H]-phlorizin binding to BBMV was used to measure the amount of SGLT1 present in the brush border membrane renal tubule. [3H]-phlorizin 35-55 Ci/mmol. (New England Nuclear. USA) binding to BBMV obtained from control and TAA-treated rats was carried out as described elsewhere (Silverman and Black, 1975). From the free and bound [3H]-phlorizin values, Scatchard plots were constructed in order to calculate the number of binding sites and their affinity. The radioactivity was measured using a LKB Rackbeta liquid scintillation counter with 35% efficiency.

Statistical analysis

All data are expressed as mean ± standard error, and the statistical significance were performed by the Student t test.

Results

TAA effects on arterial pressure and renal function.

At shown in Table 1, TAA administration to rats
produced a significant increase in glucose (P<0.05), sodium (P<0.05) and phosphate (P<0.01) urinary fractional excretion. This compound also caused a 42% decrease in the glomerular filtration rate and a 7.7% decrease in the arterial pressure (Table 1). On the other hand, there were no changes in the urinary excretion of potassium, amino acids, H⁺ nor in the blood glucose due to TAA administration.

**TAA effects on glucose tubular reabsorption**

The glucose titration curves for control and TAA-treated rats are shown in Figure 1. It could be observed that in treated animals, an increase in the load of filtered glucose was accompanied by a decrease in tubular reabsorption; this was in contrast to what was observed in controls, where an increase in the filtered glucose load occurred simultaneously with an increase in the tubular reabsorption. In controls, the Tmax G and Tmin G were of 10.77 mg/min and 8.91 mg/min, respectively. On the other hand, in the TAA-treated group the Tmax G and the Tmin G were of 4.27 mg/min (60.35% decrease in relation to control) and 2.25 mg/min (74.75% decrease in relation to control), respectively.

**BBMV relative purity**

As shown in Table 2, the BBMV fraction was enriched with the enzymes maltase and alkaline phosphatase and presented a low amount of the marker enzymes of other organelles; this result was similar to that reported by others (Malathi et al., 1979). It is interesting to point out that TAA treatment did not affect the BBMV enzymatic profile (results not shown). The electron microscopy showed vesicles of different sizes, with little or no electrondense material inside (results not shown).

**TAA effects on kinetic D-[U-¹⁴C]-glucose uptake by BBMV**

As shown in Figure 2, controls and TAA-treated BBMV [¹⁴C]-glucose uptake exhibited an overshoot at 30 sec and afterwards it declined in a similar way to that reported elsewhere (Malathi et al., 1979). The BBMV [¹⁴C]-glucose overshoot was 1350 ± 38 and 1143 ± 40 pmol of glucose/mg of proteins for control and TAA-treated rats, respectively, with difference at P<0.01.

As shown in Table 3, the [¹⁴C]-glucose uptake by BBMV kinetic parameters were similar to that reported by others (Turner and Silverman, 1977), and it could be observed that TAA treatment produced almost a 63% decrease in the Vmax and also a decrease of nearly 82% in the Km (both differences statistically significant at P<0.01).
From the Scatchard plot shown in Figure 3 the following constant for $[^3]$H-phlorizin binding to control BBMV were calculated: $K_d$ $0.98 \, \mu M$, and the number of binding sites of $79.66 \, pmols/mg$ of proteins, values that were similar to earlier reports (Olianova et al., 2001). TAA treatment decreased by 52% the $K_d$ (to $0.47 \, \mu M$), and by almost 59% the number of binding sites (to $33.02 \, pmol/mg$ of proteins).

**Table 2. BBMV enzymatic characteristics**

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Homogenate</th>
<th>BBMV</th>
<th>Relative activity</th>
<th>% Recuperation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maltase</td>
<td>$126.4 \pm 0.2$</td>
<td>$1180.5 \pm 0.3$</td>
<td>$9.4 \pm 0.2$</td>
<td>$27.4 \pm 1.2$</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>$9.1 \pm 2.1$</td>
<td>$63.8 \pm 8.0$</td>
<td>$7.0 \pm 1.8$</td>
<td>$26.0 \pm 1.4$</td>
</tr>
<tr>
<td>NADH Cyt-c reductase</td>
<td>$47.5 \pm 0.3$</td>
<td>$4.5 \pm 0.6$</td>
<td>$0.09 \pm 0.03$</td>
<td>$0.25 \pm 0.03$</td>
</tr>
<tr>
<td>$\beta$-glucuronidase</td>
<td>$29.5 \pm 0.1$</td>
<td>$10.6 \pm 0.5$</td>
<td>$0.35 \pm 0.1$</td>
<td>$1.2 \pm 0.1$</td>
</tr>
<tr>
<td>Na$^+$/K$^+$ ATPase</td>
<td>$101.9 \pm 0.4$</td>
<td>$42.7 \pm 0.5$</td>
<td>$0.45 \pm 0.1$</td>
<td>$0.9 \pm 0.1$</td>
</tr>
<tr>
<td>Succinate Cyt-c reductase</td>
<td>$37.4 \pm 0.2$</td>
<td>$1.6 \pm 0.2$</td>
<td>$0.04 \pm 0.02$</td>
<td>$0.1 \pm 0.09$</td>
</tr>
</tbody>
</table>

The BBMV were prepared following Malathi et al., (1979) and the enzymatic assays were carried out as described in Material and Methods. The values represent the means ± standard error of 3 to 5 separate experiments. The enzymatic activities are expressed as follow:

- Maltase: nmol of glucose produced/mg protein/min
- Alkaline phosphatase: mmol of p-nitrophenil phosphate/mg protein/min
- NADH Cyt-C reductase: nmol Cyt reduced/mg protein/min
- $\beta$-glucuronidase: $\mu$g phenolftalein liberated/mg protein/h
- Succinate Cyt-C reductase: nmol of Cyt-c reduced/mg protein/min

![Figure 2. TAA effect on D-[14C]-glucose uptake by BBMV](image)

BBMV obtained from control (●) and TAA-treated (○) rats were incubated with 0.2 mM D-[14C]-glucose (1 mCi/mmol) and the reaction was terminated by the fast filtration method as described Malathi et al. (1979). The radioactivity was measured using a liquid scintillation counter (LKB Rackbeta). The values represent the average of 4 separate experiments ± standard errors.

**TAA effects on [$^3$]H-phlorizin binding to BBMV**

From the Scatchard plot shown in Figure 3 the following constant for [$^3$]H-phlorizin binding to control BBMV were calculated: $K_d$ $0.98 \, \mu M$, and the number of binding sites of $79.66 \, pmols/mg$ of proteins, values that were similar to earlier reports (Olianova et al., 2001). TAA treatment decreased by 52% the $K_d$ (to $0.47 \, \mu M$), and by almost 59% the number of binding sites (to $33.02 \, pmol/mg$ of proteins).

**Table 3. TAA effects on Na$^+$/glucose cotransporter kinetic parameters**

<table>
<thead>
<tr>
<th></th>
<th>$K_m$ (mM)</th>
<th>$V_{MAX}$ (nmol/mg protein x min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>$4.16 \pm 1.18$</td>
<td>$12.63 \pm 3.57$</td>
</tr>
<tr>
<td>TAA treated</td>
<td>$0.73 \pm 0.03 ,*$</td>
<td>$4.69 \pm 0.51 ,*$</td>
</tr>
</tbody>
</table>

BBMV from control and TAA-treated rats (3 doses of 75 mg/Kg body weight) were incubated for 10 sec. at 20 ºC in 0.1 M NaCl, 0.1 M manitol, 5 mM HEPES-Tris pH 7.5 and increasing glucose concentrations (0.05-0.25 mM) in the presence of 0.1 $\mu$Ci/assay of [$^1$C]-glucose. The reaction was stopped by fast filtration with nitrocellulose membranes, and the radioactivity was counted. The $K_m$ and $V_{MAX}$ were calculated from the double reciprocal plots. The values represent the means of 3 experiments ± standard errors. *Statistically significant difference at p<0.01

**TAA effects on BBMV fluidity**

The study of the thermotropic effect of the maltase and alkaline phosphatase, obtained from the Arrhenius plots, showed the following results:

For maltase, in controls, the transition temperature was 29.6 ºC; the Activation Energy (AE) was 10.1 Kcal/mol, below the transition temperature and 7.0 Kcal/mol above it, corresponding to a 30% decrease. In membranes from TAA-treated animals, the
transition temperature, for maltase, was 27.8°C; and the AE were of 7.1 and 5.21 Kcal/mol below and above the transition temperature respectively, showing a decrease of 26.8%.

For alkaline phosphatase, in controls, the transition temperature was 29.5°C; the AE was 7.24 Kcal/mol below the transition temperature and 3.23 Kcal/mol above it, showing a decrease of 44.6%. In BBMV from TAA-treated animals the transition temperature was 28.7°C; and the AE were 6.97 and 3.3 Kcal/mol below and above the transition temperature, respectively, showing a decrease of 44.5%.

In control animals, the phospholipid/protein relationship for BBMV was 465±14 nmol/mg; and for TAA-Treated rats, it was 378±11 nmol/mg, a significant difference at P<0.01.

Table 4 illustrates the percentage of the different fatty acids present in BBMV phospholipids; there is an increase in the unsaturated fatty acids by TAA treatment (unsaturated/saturated 1.01), in comparison with the controls (unsaturated/saturated 0.86) with a greater difference in C 20:3, which increase 42.6% with drug administration.

The flotation density of the BBMV was not affected by TAA treatment, being 1.15 g/cm³.

**DISCUSSION**

It has been reported that TAA is nephrotoxic, however to cause kidney damage, either chronic (six months) exposure (Fleck et al., 1988) to the compound or a larger dose than the one used in this investigation is required (Waters et al., 2005). Furthermore, the histological examination of the kidney (results not shown) only showed an increase in the nuclei and nucleoli size of the proximal renal tubule cells, in agreement to our earlier report (Inciarte and Gonzalez-Mujica, 1988).

The decrease in the glomerular filtration rate, produced by TAA administration (Table 1), could be due to the decrease in blood pressure induced by the drug. TAA also produces glycosuria without changes in glycaemia with an increase in the fractional excretion of Na⁺ and phosphate. It has been reported (Baker and Kleinman, 1974) that an increase in the osmolar clearance of glucose increases the sodium fractional excretion. Probably, the increases in the Na⁺ and phosphate fractional excretion are due to the increases water and glucose excretion and not to a direct effect of TAA, because the function of the solute cotransporters, such as Na⁺/glucose, are directly coupled to the water flow in the kidney tubule (Loo et al., 1994). Lötischer et al., (1997) suggest that the Na⁺/phosphate cotransporter is transported from the intracellular compartment to the brush border membrane of the proximal renal tubule, in response to changes in plasma phosphate concentration. In addition, in rats, when the extracellular volume increases, the urinary elimination of Na⁺ and phosphate also increases due to changes in the Na⁺/phosphate cotransporter that are related to transduction signals including cytoskeleton proteins such as: ezrin, moesin and PDZ-dcl (Puschett et al., 2003). At present, there is no available information regarding the possibility that cytoskeleton proteins regulate the amount of the Na⁺/glucose cotransporter present in the brush border membrane of the proximal renal tubule.

It has been suggested that the height of the glucose uptake by BBMV (overshoot) depends on the membrane permeability to the anion that accompanies the cation sodium (Kessler et al., 1978; Töggemberger et al., 1978). TAA administration...
produces a substantial decrease in the glucose overshoot that suggests changes in the membrane permeability that affect the transmembrane movement of Cl⁻ and/or Na⁺ in these vesicles.

The glucose titration curves (Figure 1) prove that the glycosuric effect of TAA is due to a decrease in the glucose reabsorption capacity; furthermore the treated animals showed a lower Tmin G with respect to controls. Elsas and Rosemberg (1969) suggest that a decrease in the Tmin G indicates alterations in the kinetics parameter that in fact occur and is evidenced by a decrease in the SGLT1 Vmax induced by the TAA treatment (Table 3). The decrease in the Na⁺/glucose cotransporter Vmax implies an increase in glucose osmolar load that might explain the increase in the Na⁺ and phosphate urinary fractional excretion.

It has been suggested that Na⁺ induced conformational changes in the glucose binding site of the Na⁺/glucose cotransporter and that both sites are in the same polypeptide (Peerce and Wright, 1984; 1985). If TAA alters the Na⁺ binding to the cotransporter, its capacity to bind glucose will be reduced.

The Km and Vmax values obtained for control BBMV Na⁺/glucose cotransporter (Table 3) are similar to the system of low affinity and high capacity that operates in the first portion of the proximal renal tubule described by Turner and Moran (1982). The reduction of the SGLT1 Vmax produced by TAA administration could be due to a noncompetitive inhibition effect of the drug; however, this alteration was not observed when BBMV controls were incubated in vitro, with different concentration (1-5 mg%) of TAA (results not shown). Also, the concomitant reduction of the BBMV [³H]-phlorizin binding sites, strongly suggests that TAA acute intoxication produces a decrease in the amount of the Na⁺/glucose cotransporter present in the brush border membrane of the proximal renal tubule. This result adds evidence that TAA acts by decreasing the expression of some proteins, such as cytochrome P 450 (Sathyabama and Padmanaban, 1984) and glucose-6-phosphatase present in the rat liver nuclear envelope (González-Mujica et al., 1993).

The decrease in the Km of the Na⁺/glucose cotransporter (Table 3) and the decrease in the Kd of the binding of [³H]-phlorizin to BBMV (Figure 3) produced by TAA treatment could be due to the increase in the membrane fluidity as a consequence of the drug administration; this change in the membrane fluidity was evidenced by the increase in the relationship between unsaturated/saturated BBMV phospholipids and fatty acids and in the decrease in the transition temperature and the AE of maltase and alkaline phosphatase produced by TAA administration. It is interesting to point out that Scheel et al. (1982) reported a decrease in the Km without change in the V with and increase in the membrane fluidity.

**Acknowledgment**

The collaboration of the following persons is highly appreciated: MSc. Norma Motta for her advise in the development of this work; Dr. Atahualpa

---

**Table 4. TAA effects on the fatty acid composition of phospholipids from BBMV**

<table>
<thead>
<tr>
<th>FATTY ACID</th>
<th>CONTROLS</th>
<th>TAA TREATED</th>
<th>STATISTIC SIGNIFICANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>C 16 : 0</td>
<td>22.2 ± 0.7</td>
<td>19.9 ± 0.6</td>
<td>p&lt; 0.02</td>
</tr>
<tr>
<td>C 17 : 0</td>
<td>0.6 ± 0.05</td>
<td>0.7 ± 0.06</td>
<td>NS</td>
</tr>
<tr>
<td>C 18 : 0</td>
<td>20.0 ± 0.4</td>
<td>18.0 ± 1.0</td>
<td>p&lt; 0.01</td>
</tr>
<tr>
<td>C 18 : 2</td>
<td>10.6 ± 0.2</td>
<td>10.1 ± 0.2</td>
<td>NS</td>
</tr>
<tr>
<td>C 20 : 3</td>
<td>9.5 ± 0.6</td>
<td>9.6 ± 0.5</td>
<td>NS</td>
</tr>
<tr>
<td>C 20 : 4</td>
<td>10.8 ± 1.0</td>
<td>15.4 ± 1.5</td>
<td>p&lt; 0.01</td>
</tr>
<tr>
<td>C 20 : 5</td>
<td>22.2 ± 0.9</td>
<td>21.7 ± 0.5</td>
<td>NS</td>
</tr>
<tr>
<td>C 22 : 6</td>
<td>1.2 ± 0.06</td>
<td>0.6 ± 0.06</td>
<td>NS</td>
</tr>
<tr>
<td>C 22 : 6</td>
<td>22.2 ± 0.9</td>
<td>21.7 ± 0.5</td>
<td>NS</td>
</tr>
</tbody>
</table>

BBMV lipids from control and TAA-treated rats were separated on silica G using petroleum ether: diethyl ether: acetic acid in a proportion of 90:10:1. The fatty acids present in phospholipids were separated by gas chromatography. Data are expressed in percentages and represent the means ± standard errors of 12 separate assays with 3 rats in each. NS: not significant difference.
Pinto for performing the histological examination; and Dra. Kay Tarble de Scaramelli for correcting the manuscript.

REFERENCES


Olianova, N.; FalKm S.; Bertelot, A. 2001. Two step


